The Gordon Research Seminar on Angiotensin is a unique forum for graduate students, post-docs, and other scientists with comparable levels of experience and education to present and exchange new data and cutting edge ideas.
The focus of this meeting will be on therapies targeting the new components of the RAS; bridging the gap between basic research and clinical efficacy in pathological conditions, such as in diabetes and obesity, hypertension, aging, heart and renal failure, and auto-immune diseases.
|1:30 pm - 4:30 pm||Arrival and Check-in|
|3:00 pm - 3:15 pm||Introductory Comments by GRC Site Staff / Welcome by the GRS Conference Chair|
|3:15 pm - 4:00 pm||Keynote Session|
|Discussion Leader: Sean Thatcher (University of Kentucky)|
|3:15 pm - 3:45 pm||Dominik Mueller (Max-Delbruck-Centrum, Berlin, Germany)
"Unpredictable Results - The Big Chance in Science"
|3:45 pm - 4:00 pm||Discussion|
|4:00 pm - 5:30 pm||Poster Session I|
|5:30 pm - 7:30 pm||The RAS and Diabetes|
|Discussion Leaders: Rajesh Kumar and Candice Thomas (Texas A&M Health Science Center, Temple, TX)|
|5:30 pm - 5:50 pm||Candice Thomas (Texas A&M Health Science Center)|
"The Cardiac Renin Angiotensin System in Diabetes"
|5:50 pm - 6:00 pm||Discussion|
|6:00 pm - 6:20 pm||Katrina Binger (Max-Delbrueck Center for Molecular Medicine, Berlin, Germany)
"(Pro)renin Receptor Conditional Knockout Causes Beta-Cell Loss and Hyperglycemia by Inducing Pathological Autophagy"
|6:20 pm - 6:30 pm||Discussion|
|6:30 pm - 6:50 pm||Robin Shoemaker (Graduate Center for Nutritional Sciences, University of Kentucky)
"ACE2 Deficiency Augments the Development of Type 2 Diabetes in Obese Mice"
|6:50 pm - 7:00 pm||Discussion|
|7:00 pm - 7:20 pm||Juliana Colucci (Universidade Federal de São Paulo, Sao Paulo, Brazil) |
"Difference Between ACE/ACE2 Balance in Diabetic Mice Harboring One or Three Copies of Angiotensin Converting Enzyme Gene"
|7:20 pm - 7:30 pm||Discussion|
|7:30 am - 8:30 am||Breakfast|
|9:00 am - 11:00 am||New Therapeutics for the RAS: Targeting the ACE2/Ang-(1-7)/MasR and AT2 Receptor Pathways|
|Discussion Leaders: Kathryn Sandberg (Georgetown University, Washington DC) and Jan Danser (Erasmus MC, Rotterdam, Netherlands) |
|9:00 am - 9:20 am||Rodrigo Fraga-Silva (Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland)
"ACE2 Activators for Cardiovascular Diseases"
|9:20 am - 9:30 am||Discussion|
|9:30 am - 9:50 am||Robert Regenhardt (University of Florida, Gainesville, FL)|
"Transcriptomic Modeling of the Cerebroprotective Effects of AT2R Agonist Compound 21 in Ischemic Stroke"
|9:50 am - 10:00 am||Discussion|
|10:00 am - 10:20 am||Emma Jones (Monash University, Melbourne, Australia)
"Pharmacology of Novel AT2 Receptor Agonists"
|10:20 am - 10:30 am||Discussion|
|10:30 am - 10:50 am||Gerry Wagenaar (Leiden University Medical Center, Leiden, Netherlands)
"Intervening in AT2 Signalling Attenuates Hyperoxia-Induced Lung and Heart Injury in Newborn Rats"
|10:50 am - 11:00 am||Discussion|
|11:00 am - 12:30 pm||Poster Session II|
|Coffee will be served in the poster area from 11:00 am - 11:30 am|
|1:30 pm - 2:30 pm||New Developments and Signaling in the RAS|
|Discussion Leaders: Alan Daugherty (University of Kentucky, Lexington, KY) and Johannes Stegbauer (UKD, Dusseldorf, Germany)|
|1:30 pm - 1:50 pm||Eva Königshausen (UKD, Dusseldorf, Germany)
"Ang II Promotes Beta-Arrestin 2 Mediated Endocytosis in Podocytes"
|1:50 pm - 2:00 pm||Discussion|
|2:00 pm - 2:20 pm||Qian Chen Yong (Texas A&M Health Science Center, Temple, TX)|
"Hydrogen Sulfide Inhibits the Activation of the Renin-Angiotensin System in Diabetic Heart"
|2:20 pm - 2:30 pm||Discussion|
|2:30 pm - 3:00 pm||Evaluation Period|
|Fill in GRS Evaluation Forms|
|3:00 pm||Seminar Concludes|
Funding for this conference was made possible (in part) by 1R13HL121852-01A1 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.